Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

Benzinga · 1d ago
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $271 to $275.